Peter L. Turecek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter L. Turecek has a total of 194 co-authors. Here are the top co-authors by number of shared publications:
Herbert Gritsch
Analytical Development Europe, Baxalta Innovations GmbH, a Takeda company, Vienna, Austria
8 shared publicationsMichael Spannagl
LMU University Hospital
4 shared publicationsAlfred Weber
Plasma‐Derived Therapies R&D Baxalta Innovations GmbH, part of Takeda Vienna Austria
3 shared publications- François Depasse
Diagnostica Stago
3 shared publications Gerald Schrenk
Analytical Development Europe, Baxalta Innovations GmbH, a Takeda company, Vienna, Austria
3 shared publications- Jürgen Patzke
Independent Researcher, 35043 Marburg, Germany
3 shared publications
Latest Publications
- Open Access
- 24 August 2026
- Published by American Society of Hematology in Blood
Whole genome sequencing to elucidate novel genetic modifiers of FVIII clearance.
Despite significant insights into factor VIII (FVIII) biosynthesis, the mechanisms involved in FVIII clearance remain poorly defined. To investigate genetic modifiers of FVIII clearance, we studied 106 SNPs across 43 different loci previously reported to influence plasma FVIII and/or von Willebrand (VWF) levels and reviewed their association with FVIII pharmacokinetic (PK) parameters in 52 patients with hemophilia A. Marked inter-individual variability in FVIII clearance was observed. Plasma VWF levels, ABO blood group and age all influenced FVIII PK parameters. Collectively however, linear regression analysis demonstrated that these explained less than 40% of the observed variance in FVIII clearance. Consistent with previous reports, SNPs mapped to the FVIII/VWF clearance receptors STAB2, ASGR2, and CLEC4M were associated with FVIII clearance. Importantly however, we identified four additional genetic signals marked by SNPs rs4904820 (TC2N), rs3124768 (ADAMTS13), rs12979891 (RASIP1/MAMSTR/FUT2) and rs6494314 (C2CD4B) that were also significantly associated with FVIII PK parameters. Of particular interest, the FUT2 gene on chromosome 19q13 determines Secretor blood group status and thus determines secretion of ABO(H) glycan determinants into plasma. In addition to the association between the rs12979891 SNP and FVIII clearance, we further observed an effect of Secretor genotype on FVIII PK parameters, with prolonged FVIII half-life in non-secretor individuals compared to homozygous secretors. Furthermore, plasma FVIII levels were significantly increased in Fut2 knockout mice. Cumulatively, these data identify novel modifiers of FVIII clearance in vivo. Given that plasma FVIII levels constitute a dose-dependent risk factor for cardiovascular disease, these findings are of direct clinical importance.
- 24 August 2026
- Published by American Society of Hematology in Blood
Open AccessWhole genome sequencing to elucidate novel genetic modifiers of FVIII clearance.
Despite significant insights into factor VIII (FVIII) biosynthesis, the mechanisms involved in FVIII clearance remain poorly defined. To investigate genetic modifiers of FVIII clearance, we studied 106 SNPs across 43 different loci previously reported to influence plasma FVIII and/or von Willebrand (VWF) levels and reviewed their association with FVIII pharmacokinetic (PK) parameters in 52 patients with hemophilia A. Marked inter-individual variability in FVIII clearance was observed. Plasma VWF levels, ABO blood group and age all influenced FVIII PK parameters. Collectively however, linear regression analysis demonstrated that these explained less than 40% of the observed variance in FVIII clearance. Consistent with previous reports, SNPs mapped to the FVIII/VWF clearance receptors STAB2, ASGR2, and CLEC4M were associated with FVIII clearance. Importantly however, we identified four additional genetic signals marked by SNPs rs4904820 (TC2N), rs3124768 (ADAMTS13), rs12979891 (RASIP1/MAMSTR/FUT2) and rs6494314 (C2CD4B) that were also significantly associated with FVIII PK parameters. Of particular interest, the FUT2 gene on chromosome 19q13 determines Secretor blood group status and thus determines secretion of ABO(H) glycan determinants into plasma. In addition to the association between the rs12979891 SNP and FVIII clearance, we further observed an effect of Secretor genotype on FVIII PK parameters, with prolonged FVIII half-life in non-secretor individuals compared to homozygous secretors. Furthermore, plasma FVIII levels were significantly increased in Fut2 knockout mice. Cumulatively, these data identify novel modifiers of FVIII clearance in vivo. Given that plasma FVIII levels constitute a dose-dependent risk factor for cardiovascular disease, these findings are of direct clinical importance.
- Open Access
- 20 July 2026
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 19 (9) , 1037-1057
Clinical laboratory diagnostics and monitoring of ADAMTS13 deficiency and of related diseases: an integrated approach
ADAMTS13, a crucial enzyme in hemostasis, that specifically cleaves von Willebrand factor (VWF), plays a pivotal role in the pathogenesis and diagnosis of thrombotic thrombocytopenic purpura (TTP), a microcirculatory form of thrombotic microangiopathy (TMA). Its deficiency leads to the accumulation of ultra-large VWF multimers, causing microvascular thrombosis. Understanding and measuring ADAMTS13 activity are essential for diagnosis and management of TTP and other thrombotic diseases associated with ADAMTS13 deficiency. This review explores the evolution of ADAMTS13 assays from labor-intensive methods to rapid, automated platforms. It examines congenital and acquired ADAMTS13 deficiencies, highlighting diagnostic strategies and therapeutic interventions. A comprehensive literature search was conducted between September 2025 and June 2026 using PubMed and GoogleScholar, focusing on recent advancements and extending to foundational studies when necessary. The integration of rapid ADAMTS13 testing has the potential to improve clinical decision-making by shortening diagnostic uncertainty and supporting earlier differentiation of TTP from other TMAs. Despite progress, challenges remain in assay standardization, sensitivity, and interpretation. Future developments may include point-of-care technologies and conformation-sensitive assays to enhance relapse prediction and monitoring. Collaboration between clinicians and laboratories is crucial to optimize patient outcomes and advance the field of ADAMTS13 diagnostics.
- 20 July 2026
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 19 (9) , 1037-1057
Open AccessClinical laboratory diagnostics and monitoring of ADAMTS13 deficiency and of related diseases: an integrated approach
ADAMTS13, a crucial enzyme in hemostasis, that specifically cleaves von Willebrand factor (VWF), plays a pivotal role in the pathogenesis and diagnosis of thrombotic thrombocytopenic purpura (TTP), a microcirculatory form of thrombotic microangiopathy (TMA). Its deficiency leads to the accumulation of ultra-large VWF multimers, causing microvascular thrombosis. Understanding and measuring ADAMTS13 activity are essential for diagnosis and management of TTP and other thrombotic diseases associated with ADAMTS13 deficiency. This review explores the evolution of ADAMTS13 assays from labor-intensive methods to rapid, automated platforms. It examines congenital and acquired ADAMTS13 deficiencies, highlighting diagnostic strategies and therapeutic interventions. A comprehensive literature search was conducted between September 2025 and June 2026 using PubMed and GoogleScholar, focusing on recent advancements and extending to foundational studies when necessary. The integration of rapid ADAMTS13 testing has the potential to improve clinical decision-making by shortening diagnostic uncertainty and supporting earlier differentiation of TTP from other TMAs. Despite progress, challenges remain in assay standardization, sensitivity, and interpretation. Future developments may include point-of-care technologies and conformation-sensitive assays to enhance relapse prediction and monitoring. Collaboration between clinicians and laboratories is crucial to optimize patient outcomes and advance the field of ADAMTS13 diagnostics.
- Open Access
- 18 December 2025
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 24 (2) , 785
Corrigendum to ‘Real-world use of protein C concentrate for the treatment of patients with protein C deficiency: an international registry’
- 18 December 2025
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 24 (2) , 785
Open AccessCorrigendum to ‘Real-world use of protein C concentrate for the treatment of patients with protein C deficiency: an international registry’
- Open Access
- 7 September 2025
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 44 (6) , 451-457
Evaluation of Plasma Polyethylene Glycol (PEG) Levels in a Healthy Adult Population
Polyethylene glycols (PEGs) are amphiphilic polymers that are used extensively in consumer products and PEGylated biotherapeutics. Although PEGs are considered biologically inert with a low toxicity, anti-PEG antibodies have been detected in patients receiving treatment with PEGylated biotherapeutics as well as in healthy individuals. Despite continual exposure in daily life, the prevalence of PEGs within the general population remains unclear. This study aimed to evaluate a healthy population for the presence of PEGs. A validated enzyme-linked immunosorbent assay (ELISA) platform was used to analyze 200 plasma samples from healthy adults for the presence of PEGs. High-performance liquid chromatography–tandem mass spectrometry (HPLC-MS/MS) was also used to analyze the samples for the presence of four PEG analytes: PEG3350; PEG4000; PEG10000; and PEG2ru20K COOH, a 20 kDa PEG used to modify therapeutic proteins. The detection limit for PEG3350 calculated by extrapolation with linear regression was assumed to be 3.60 ng/mL. PEG levels above the lower limit of quantification (LLOQ) (21.6 ng/mL) were detected in 41 plasma samples, range 22.1-43.9 ng/mL, using the ELISA platform. None of the samples were found to contain detectable levels of PEG4000, PEG10000, or PEG2ru20K COOH. Following extrapolation, PEG3350 levels above the LLOQ (3.60 ng/mL) were detected in 154 plasma samples, range 3.69-46.0 ng/mL. Using an ELISA platform and HPLC-MS/MS analysis, PEGs were detected in the plasma of 77.4% of healthy adults. The findings are suggestive that expanding worldwide exposure to PEGs may have resulted in a much higher incidence of detectable plasma burdens of PEG than was previously realized.
- 7 September 2025
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 44 (6) , 451-457
Open AccessEvaluation of Plasma Polyethylene Glycol (PEG) Levels in a Healthy Adult Population
Polyethylene glycols (PEGs) are amphiphilic polymers that are used extensively in consumer products and PEGylated biotherapeutics. Although PEGs are considered biologically inert with a low toxicity, anti-PEG antibodies have been detected in patients receiving treatment with PEGylated biotherapeutics as well as in healthy individuals. Despite continual exposure in daily life, the prevalence of PEGs within the general population remains unclear. This study aimed to evaluate a healthy population for the presence of PEGs. A validated enzyme-linked immunosorbent assay (ELISA) platform was used to analyze 200 plasma samples from healthy adults for the presence of PEGs. High-performance liquid chromatography–tandem mass spectrometry (HPLC-MS/MS) was also used to analyze the samples for the presence of four PEG analytes: PEG3350; PEG4000; PEG10000; and PEG2ru20K COOH, a 20 kDa PEG used to modify therapeutic proteins. The detection limit for PEG3350 calculated by extrapolation with linear regression was assumed to be 3.60 ng/mL. PEG levels above the lower limit of quantification (LLOQ) (21.6 ng/mL) were detected in 41 plasma samples, range 22.1-43.9 ng/mL, using the ELISA platform. None of the samples were found to contain detectable levels of PEG4000, PEG10000, or PEG2ru20K COOH. Following extrapolation, PEG3350 levels above the LLOQ (3.60 ng/mL) were detected in 154 plasma samples, range 3.69-46.0 ng/mL. Using an ELISA platform and HPLC-MS/MS analysis, PEGs were detected in the plasma of 77.4% of healthy adults. The findings are suggestive that expanding worldwide exposure to PEGs may have resulted in a much higher incidence of detectable plasma burdens of PEG than was previously realized.
- Open Access
- 29 July 2025
- Published by Wiley in Haemophilia
- Vol. 31 (5) , 1043-1053
Spinal Stenosis: An Emerging Complication of Ageing in People With Haemophilia
Introduction: Advances in haemophilia care have brought the challenges of ageing for people with haemophilia (PWH) to the forefront. Age‐related spinal degeneration may result in spinal stenosis; however, the rates in PWH are unknown. We sought to systematically review Irish PWH to address this gap in the current literature. Methods: Clinical and radiological notes of all patients ≥40 years old (yo) registered with severe or moderate haemophilia A or B were reviewed, recording Haemophilia Joint Health Scores (HJHS), radiological imaging and orthopaedic/pain interventions. Results: Of 100 males included with moderate or severe haemophilia, 13% had radiologically confirmed symptomatic spinal stenosis (reported rates 4% in the general population aged >60 yo). Persons with stenosis were older (median age 69yo vs. 55 yo, p = 0.004) with similar rates observed between those with moderate and severe haemophilia (4/35, 11.4% vs. 9/65, 13.8%). HJHS did not differ between those with and without stenosis (median 30 vs. 35, p = 0.6). On regression analysis, only age >60 yo was associated with an increased likelihood of spinal stenosis; severity of haemophilia (moderate vs. severe) was not significantly associated. Conclusions: These data identify symptomatic spinal stenosis as a novel complication of ageing for PWH. Spinal stenosis rates were higher than expected for age in comparison to reported rates in the general population. Current joint assessments fail to capture spinal pathology, highlighting limitations of HJHS in older PWH. Increased awareness amongst PWH and health care providers of spinal stenosis is directly required; however, optimal management strategies for PWH with established stenosis are yet to be defined.
- 29 July 2025
- Published by Wiley in Haemophilia
- Vol. 31 (5) , 1043-1053
Open AccessSpinal Stenosis: An Emerging Complication of Ageing in People With Haemophilia
Introduction: Advances in haemophilia care have brought the challenges of ageing for people with haemophilia (PWH) to the forefront. Age‐related spinal degeneration may result in spinal stenosis; however, the rates in PWH are unknown. We sought to systematically review Irish PWH to address this gap in the current literature. Methods: Clinical and radiological notes of all patients ≥40 years old (yo) registered with severe or moderate haemophilia A or B were reviewed, recording Haemophilia Joint Health Scores (HJHS), radiological imaging and orthopaedic/pain interventions. Results: Of 100 males included with moderate or severe haemophilia, 13% had radiologically confirmed symptomatic spinal stenosis (reported rates 4% in the general population aged >60 yo). Persons with stenosis were older (median age 69yo vs. 55 yo, p = 0.004) with similar rates observed between those with moderate and severe haemophilia (4/35, 11.4% vs. 9/65, 13.8%). HJHS did not differ between those with and without stenosis (median 30 vs. 35, p = 0.6). On regression analysis, only age >60 yo was associated with an increased likelihood of spinal stenosis; severity of haemophilia (moderate vs. severe) was not significantly associated. Conclusions: These data identify symptomatic spinal stenosis as a novel complication of ageing for PWH. Spinal stenosis rates were higher than expected for age in comparison to reported rates in the general population. Current joint assessments fail to capture spinal pathology, highlighting limitations of HJHS in older PWH. Increased awareness amongst PWH and health care providers of spinal stenosis is directly required; however, optimal management strategies for PWH with established stenosis are yet to be defined.
- Open Access
- 22 July 2025
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 23 (11) , 3569-3577
Real-world use of protein C concentrate for the treatment of patients with protein C deficiency: an international registry
- 22 July 2025
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 23 (11) , 3569-3577
Open AccessReal-world use of protein C concentrate for the treatment of patients with protein C deficiency: an international registry
- Open Access
- 18 July 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (16) , 1979-1990
The interleukin-33 receptor (ST2) is a novel therapeutic target to attenuate the progression of hemophilic arthropathy
Haemophilia A is an X-linked bleeding disorder caused by a blood clotting protein factor VIII deficiency. Patients with haemophilia develop recurrent bleeding episodes. When bleeding occurs in the joints, haemophilic arthropathy (HA) may develop, resulting in hemarthroses and joint deformation. A novel congenic mouse model of severe haemophilia A was generated using CRISPR/Cas9 targeting of exon-1 of the F8 gene (F8em1-/-) to explore changes in the bleeding and inflammation during HA. F8em1-/- mice have a high penetrance of spontaneous bleeding, with joint bleeds progressing to arthropathy. F8em1-/- mice were subjected to needle-induced damage to the knee to assess synchronised joint bleeding, and the development of HA and synovial inflammation was assessed. The synovium of injured joints of F8em1-/- mice had differential and temporal expression of inflammatory genes after injury. Pathway analysis identified upregulation of the IL-1 family cytokines, IL-1b and IL-33, and respective receptors IL-1RAP and T1/ST2 (ST2) in the synovium of mice after needle-induced HA. Soluble ST2 and IL-33 levels were elevated in the plasma of F8em1-/- mice in acute stages after needle injury to the joints. Dual ST2 deficient F8em1-/- mice were generated, with ST2 deficient haemophilic mice developing significantly reduced joint damage after needle injury relative to F8em1-/- mice. Using a therapeutic intervention, blocking ST2 following joint injury significantly ameliorated joint damage during HA in haemophilic mice. These studies in a new mouse model of HA identify a crucial role of ST2 in HA pathogenesis and highlight its potential as a novel therapeutic target.
- 18 July 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (16) , 1979-1990
Open AccessThe interleukin-33 receptor (ST2) is a novel therapeutic target to attenuate the progression of hemophilic arthropathy
Haemophilia A is an X-linked bleeding disorder caused by a blood clotting protein factor VIII deficiency. Patients with haemophilia develop recurrent bleeding episodes. When bleeding occurs in the joints, haemophilic arthropathy (HA) may develop, resulting in hemarthroses and joint deformation. A novel congenic mouse model of severe haemophilia A was generated using CRISPR/Cas9 targeting of exon-1 of the F8 gene (F8em1-/-) to explore changes in the bleeding and inflammation during HA. F8em1-/- mice have a high penetrance of spontaneous bleeding, with joint bleeds progressing to arthropathy. F8em1-/- mice were subjected to needle-induced damage to the knee to assess synchronised joint bleeding, and the development of HA and synovial inflammation was assessed. The synovium of injured joints of F8em1-/- mice had differential and temporal expression of inflammatory genes after injury. Pathway analysis identified upregulation of the IL-1 family cytokines, IL-1b and IL-33, and respective receptors IL-1RAP and T1/ST2 (ST2) in the synovium of mice after needle-induced HA. Soluble ST2 and IL-33 levels were elevated in the plasma of F8em1-/- mice in acute stages after needle injury to the joints. Dual ST2 deficient F8em1-/- mice were generated, with ST2 deficient haemophilic mice developing significantly reduced joint damage after needle injury relative to F8em1-/- mice. Using a therapeutic intervention, blocking ST2 following joint injury significantly ameliorated joint damage during HA in haemophilic mice. These studies in a new mouse model of HA identify a crucial role of ST2 in HA pathogenesis and highlight its potential as a novel therapeutic target.
- Open Access
- 9 July 2025
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 18 (9) , 701-718
Von Willebrand factor is a multifaceted player in hemostasis requiring a diverse array of analytical and diagnostic approaches
Von Willebrandfactor (VWF) plays a crucial role in hemostasis: its interactions with endothelialmatrices, platelets, and factor VIII make it a key player in both primaryhemostasis and coagulation. Pathology associated with VWF spans mild to severebleeding manifestations in the case of inherited von Willebrand disease (VWD),the most common congenital bleeding disorder, or acquired von Willebrandsyndrome (AVWS). Conversely, VWF can be associated with thromboticmanifestations in situations related to inflammation, infection, or inheritedor acquired ADAMTS13 defects. This reviewarticle aims to provide guidance on the use and interpretation of clinicallaboratory assays available to measure VWF and other factors related to VWD.Different VWF tests can be used in different clinical settings for efficientdiagnosis and patient management. Assay limitations are also addressed. A myriad oflaboratory assays, from first line to esoteric assays, exist to enable adequatediagnosis of VWD and other diseases influenced by VWF. Clinical investigationsof VWF are complicated because VWF has multiple functions which variably dependon the patient's pathophysiological status. The right choice of assays istherefore critical to provide adequate diagnosis in due time and withreasonable analytical efforts.
- 9 July 2025
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 18 (9) , 701-718
Open AccessVon Willebrand factor is a multifaceted player in hemostasis requiring a diverse array of analytical and diagnostic approaches
Von Willebrandfactor (VWF) plays a crucial role in hemostasis: its interactions with endothelialmatrices, platelets, and factor VIII make it a key player in both primaryhemostasis and coagulation. Pathology associated with VWF spans mild to severebleeding manifestations in the case of inherited von Willebrand disease (VWD),the most common congenital bleeding disorder, or acquired von Willebrandsyndrome (AVWS). Conversely, VWF can be associated with thromboticmanifestations in situations related to inflammation, infection, or inheritedor acquired ADAMTS13 defects. This reviewarticle aims to provide guidance on the use and interpretation of clinicallaboratory assays available to measure VWF and other factors related to VWD.Different VWF tests can be used in different clinical settings for efficientdiagnosis and patient management. Assay limitations are also addressed. A myriad oflaboratory assays, from first line to esoteric assays, exist to enable adequatediagnosis of VWD and other diseases influenced by VWF. Clinical investigationsof VWF are complicated because VWF has multiple functions which variably dependon the patient's pathophysiological status. The right choice of assays istherefore critical to provide adequate diagnosis in due time and withreasonable analytical efforts.
- Open Access
- 4 July 2025
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 19 (8) , 1-15
Review of laboratory methods used for analysis of von Willebrand factor and for diagnosis of related diseases
Von Willebrand factor (VWF) is a large multimeric protein present in the blood. Its most important and best characterized function is to control bleeding in primary hemostasis, which is triggered by different biophysical mechanisms and protein-receptor interactions involving different domains of VWF. Many different diseases related to VWF, most importantly von Willebrand disease comprising different types and sub-types, require diagnosis, laboratory analysis of concentration, and function of VWF. As several different specific functions of VWF are physiologically relevant, several different assays are needed. The aim of this article is to provide a comprehensive overview of all relevant assays together with a description of how each assay is technically designed. Furthermore, guidance is given for choosing the right and validated assay methods. This information includes technical requirements, analytical performance data, references to relevant guidelines and other guidance documents, and reference standards. Also, information on availability and the type of the assay is provided, such as automated or manual, in vitro diagnostics or research use only. Relation to the clinical use of these assays, as well as performance, and result interpretation is covered in a second article in the same issue of this journal by the same authors.
- 4 July 2025
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 19 (8) , 1-15
Open AccessReview of laboratory methods used for analysis of von Willebrand factor and for diagnosis of related diseases
Von Willebrand factor (VWF) is a large multimeric protein present in the blood. Its most important and best characterized function is to control bleeding in primary hemostasis, which is triggered by different biophysical mechanisms and protein-receptor interactions involving different domains of VWF. Many different diseases related to VWF, most importantly von Willebrand disease comprising different types and sub-types, require diagnosis, laboratory analysis of concentration, and function of VWF. As several different specific functions of VWF are physiologically relevant, several different assays are needed. The aim of this article is to provide a comprehensive overview of all relevant assays together with a description of how each assay is technically designed. Furthermore, guidance is given for choosing the right and validated assay methods. This information includes technical requirements, analytical performance data, references to relevant guidelines and other guidance documents, and reference standards. Also, information on availability and the type of the assay is provided, such as automated or manual, in vitro diagnostics or research use only. Relation to the clinical use of these assays, as well as performance, and result interpretation is covered in a second article in the same issue of this journal by the same authors.
- Open Access
- 5 June 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (23) , 2768-2773
Enhanced α2-3–linked sialylation determines the extended half-life of CHO-rVWF
The half-life of recombinant human von Willebrand factor (rVWF) expressed in CHO cells (CHO-rVWF; Vonicog alfa; and Vonvendi/Veyvondi) is significantly longer than that of plasma-derived VWF (pdVWF). This finding is intriguing because CHO cells do not generate α2-6 sialylation, which constitutes the majority of human pdVWF sialylation. We hypothesized that glycan differences might regulate the longer half-life of CHO-rVWF. In lectin plate-binding assays and liquid chromatography–mass spectrometry analysis, we confirmed that CHO-rVWF lacked α2-6–linked sialylation. Conversely, however, α2-3–linked sialylation was significantly increased on CHO-rVWF, which also had reduced exposed β-galactose (β-Gal) compared to pdVWF. Consistent with human data, CHO-rVWF clearance was significantly (P < .001) reduced in VWF–/– mice compared to pdVWF. However, clearance of asialo-pdVWF and asialo–CHO-rVWF were identical. In keeping with the in vivo half-life prolongation, CHO-rVWF binding to murine macrophages (P = .012) and HepG2 cells (P = .001) was significantly decreased compared to pdVWF. Furthermore, CHO-rVWF binding to purified macrophage-galactose-type lectin (MGL) receptor and asialoglycoprotein receptor (ASGPR) was also significantly reduced. In contrast to pdVWF, in vivo studies in MGL1–/– mice and Asgr1–/– mice demonstrated that neither MGL nor ASGPR plays significant roles in regulating CHO-rVWF clearance. Together, our findings demonstrate that enhanced α2-3–linked sialylation on CHO-rVWF is responsible for its extended half-life.
- 5 June 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (23) , 2768-2773
Open AccessEnhanced α2-3–linked sialylation determines the extended half-life of CHO-rVWF
The half-life of recombinant human von Willebrand factor (rVWF) expressed in CHO cells (CHO-rVWF; Vonicog alfa; and Vonvendi/Veyvondi) is significantly longer than that of plasma-derived VWF (pdVWF). This finding is intriguing because CHO cells do not generate α2-6 sialylation, which constitutes the majority of human pdVWF sialylation. We hypothesized that glycan differences might regulate the longer half-life of CHO-rVWF. In lectin plate-binding assays and liquid chromatography–mass spectrometry analysis, we confirmed that CHO-rVWF lacked α2-6–linked sialylation. Conversely, however, α2-3–linked sialylation was significantly increased on CHO-rVWF, which also had reduced exposed β-galactose (β-Gal) compared to pdVWF. Consistent with human data, CHO-rVWF clearance was significantly (P < .001) reduced in VWF–/– mice compared to pdVWF. However, clearance of asialo-pdVWF and asialo–CHO-rVWF were identical. In keeping with the in vivo half-life prolongation, CHO-rVWF binding to murine macrophages (P = .012) and HepG2 cells (P = .001) was significantly decreased compared to pdVWF. Furthermore, CHO-rVWF binding to purified macrophage-galactose-type lectin (MGL) receptor and asialoglycoprotein receptor (ASGPR) was also significantly reduced. In contrast to pdVWF, in vivo studies in MGL1–/– mice and Asgr1–/– mice demonstrated that neither MGL nor ASGPR plays significant roles in regulating CHO-rVWF clearance. Together, our findings demonstrate that enhanced α2-3–linked sialylation on CHO-rVWF is responsible for its extended half-life.